We hypothesize that 18FDG Positron Emission Tomography (FDG PET) imaging, carried out after
the first cycle of chemotherapy, will identify responders, thus permitting early termination
of potential toxic therapy in non- responders leading to a significant decrease in morbidity
and cost. The value of PET imaging as an early predictor of response to chemotherapy has
been shown in other cancers.
- Histologically proven ovarian cancer at diagnosis of any stage.
- Patients with evidence of disease that is radiographically measurable (CT scan)
- Patients have planned to undergo standard chemotherapy. Dose and schedule will be
determined per treating physician
- Patients with any other malignancy active within 5 years except for non-melanoma skin
cancer, or carcinoma in situ of the cervix.
- Patients with an active infection
- Patients of childbearing potential are excluded from this study.
- Patients who have expected survival < 3 months.
- Patients not planning or able to receive the outlined chemotherapy regimen as part of
- Patient unable to complete study